6504 ORAL Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma

J.L. Dikken, A.E. Dassen, V.E.P. Lemmens, L. van der Geest, K. Bosscha, M. Verheij, C.J.H. van de Velde, M.W.J.M. Wouters. Leiden University Medical Center, Surgical Oncology, Leiden, The Netherlands; Jeroen Bosch Ziekenhuis, Surgery, Den Bosch, The Netherlands; Comprehensive Cancer Center, South, Eindhoven, The Netherlands; Comprehensive Cancer Center, The Netherlands, Leiden, The Netherlands; The Netherlands Cancer Institute − Antoni van Leeuwenhoek Hospital, Radiotherapy, Amsterdam, The Netherlands; Leiden University Medical Center, Surgery, Leiden, The Netherlands; The Netherlands Cancer Institute − Antoni van Leeuwenhoek Hospital, Surgery, Amsterdam, The Netherlands